We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · July 22, 2021

Clinical and Molecular Characteristics of HER2–Low-Positive Breast Cancer

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Clinical and Molecular Characteristics of HER2-Low-Positive Breast Cancer: Pooled Analysis of Individual Patient Data From Four Prospective, Neoadjuvant Clinical Trials
Lancet Oncol 2021 Jul 09;[EPub Ahead of Print], C Denkert, F Seither, A Schneeweiss, T Link, JU Blohmer, M Just, P Wimberger, A Forberger, H Tesch, C Jackisch, S Schmatloch, M Reinisch, EF Solomayer, WD Schmitt, C Hanusch, PA Fasching, K Lübbe, C Solbach, J Huober, K Rhiem, F Marmé, T Reimer, M Schmidt, BV Sinn, W Janni, E Stickeler, L Michel, O Stötzer, E Hahnen, J Furlanetto, S Seiler, V Nekljudova, M Untch, S Loibl

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading